Height, Obesity, and the Risk of -Defined Prostate Cancer.

TitleHeight, Obesity, and the Risk of -Defined Prostate Cancer.
Publication TypeJournal Article
Year of Publication2018
AuthorsGraff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Heiden MGVander, Fiorentino M, Giovannucci EL, Loda M, Mucci LA
JournalCancer Epidemiol Biomarkers Prev
Volume27
Issue2
Pagination193-200
Date Published2018 02
ISSN1538-7755
KeywordsAdult, Aged, Body Height, Body Mass Index, Body Weight, Follow-Up Studies, Humans, Male, Middle Aged, Obesity, Oncogene Proteins, Fusion, Prospective Studies, Prostatic Neoplasms, Risk Factors, Transcriptional Regulator ERG
Abstract

The largest molecular subtype of primary prostate cancer is defined by the gene fusion. Few studies, however, have investigated etiologic differences by status. Because the fusion is hormone-regulated and a man's hormonal milieu varies by height and obesity status, we hypothesized that both may be differentially associated with risk of -defined disease. Our study included 49,372 men from the prospective Health Professionals Follow-up Study. Participants reported height and weight at baseline in 1986 and updated weight biennially thereafter through 2009. Tumor ERG protein expression (a marker) was immunohistochemically assessed. We used multivariable competing risks models to calculate HRs and 95% confidence intervals (CIs) for the risk of ERG-positive and ERG-negative prostate cancer. During 23 years of follow-up, we identified 5,847 incident prostate cancers, among which 913 were ERG-assayed. Taller height was associated with an increased risk of ERG-positive disease only [per 5 inches HR 1.24; 95% confidence interval (CI), 1.03-1.50; = 0.07]. Higher body mass index (BMI) at baseline (per 5 kg/m HR 0.75; 95% CI, 0.61-0.91; = 0.02) and updated BMI over time (per 5 kg/m HR 0.86; 95% CI, 0.74-1.00; = 0.07) were associated with a reduced risk of ERG-positive disease only. Our results indicate that anthropometrics may be uniquely associated with -positive prostate cancer; taller height may be associated with greater risk, whereas obesity may be associated with lower risk. Our study provides strong rationale for further investigations of other prostate cancer risk factors that may be distinctly associated with subtypes. .

DOI10.1158/1055-9965.EPI-17-0547
Alternate JournalCancer Epidemiol Biomarkers Prev
PubMed ID29167279
PubMed Central IDPMC5809280
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
P01 CA087969 / CA / NCI NIH HHS / United States
R25 CA112355 / CA / NCI NIH HHS / United States
U01 CA167552 / CA / NCI NIH HHS / United States
R01 CA131945 / CA / NCI NIH HHS / United States
UM1 CA186107 / CA / NCI NIH HHS / United States
T32 CA009001 / CA / NCI NIH HHS / United States
R01 CA136578 / CA / NCI NIH HHS / United States
/ HHMI / Howard Hughes Medical Institute / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700